On international Women Human Rights Defenders Day, FIGO stands with partners and allies to support the launch a new set of ...

"This protocol represents a significant step forward in standardising care for women recovering from vesicovaginal fistula ...

This World Prematurity Day, FIGO calls on healthcare providers, policymakers, and communities to champion better care for ...

We have recently witnessed some policy changes that have led to the expanded registration of mifepristone, a crucial medication used for medical abortion, in various countries. This expansion is a ...

FIGO’s Improving access to essential medicines to reduce postpartum haemorrhage (PPH) morbidity and mortality (IAP) project ...

FIGO and the World Health Organization (WHO) are collaborating to enhance family planning care globally, by increasing ...

FIGO’s Self-Management of Abortion (SMA) Project, which concluded in May 2024, worked to implement WHO Abortion Guideline on ...

Project leads: Professor Sean Kehoe, Past Chair and current member of the FIGO Committee on Women's Cancer; Professor Joanna ...

FIGO’s Accelerating Measurable Progress and Leveraging Investments for Postpartum Haemorrhage Impact (AMPLI-PPHI) project ...

FIGO’s Combatting Post-Partum Hemorrhage (PPH) project aims to provide technical support to selected regional and national ...

The key goal of the FIGO Saving Mothers and Newborns Initiative was to contribute to the reduction in maternal and newborn ...

Background: Post-partum haemorrhage (PPH) is the most significant direct cause of maternal mortality in low-resource ...